[{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyra Therapeutics Announces FDA Clearance of Investigational New Drug Application for a Phase 2 Clinical Trial of LYR-210 for Chronic Rhinosinusitis","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Lyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Decibel Therapeutics to Present at the 43rd Annual Association for Research in Otolaryngology (ARO) Conference","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"DB-020","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Decibel Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Decibel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Presents New SENS-401 Preclinical Data at ARO Midwinter Meeting 2020","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Azasetron","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Receives Ethics Committee Approval to Include New Military Sites in SENS-401 Phase 2 study","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Azasetron","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion gets approval to add new sites to Phase II trial of SENS-401","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Azasetron","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$58.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lyra Therapeutics wants a $58M IPO\n","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Public Offering","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fennec Announces Issuance of U.S. Patent for Use of PEDMARK\u2122","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Fennec Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Fennec Pha.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion provides update on SENS-401 SSNHL Phase 2 AUDIBLE-S trial enrollment","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Azasetron","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Not Applicable ","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Novus Therapeutics, Inc","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novus Therapeutics Completes Enrollment of Phase 2a Trial of OP0201 in Pediatric Patients with Acute Otitis Media","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"DPPC","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Novus Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novus Therapeutics, Inc \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Novus Ther.."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Decibel Therapeutics Publishes Results from Early-Stage Study of Therapy Designed to Prevent Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex binder","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Decibel Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Transtympanic Injection","sponsorNew":"Decibel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Auditus","sponsor":"Oblato","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oblato Biotech Company Acquires Hearing Loss Drug","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Acetylcysteine","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Auditus","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Auditus \/ Oblato","highestDevelopmentStatusID":"8","companyTruncated":"Auditus \/ .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK's asthma biologic Nucala is one step closer to approval in key chronic rhinosinusitis population","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Mepolizumab","moa":"IL-5","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Provides Business Update Related to COVID-19 Pandemic","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fennec Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of New Drug Application for PEDMARK\u2122","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Fennec Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"Fennec Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fennec Pha.."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Shares Clinical Data From Exploratory Study Confirming Delivery of FX-322 to the Cochlea","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"St. Jude Children","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Blue Water Licenses Patent Rights for bacterial Vaccine Development","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Streptococcus Pneumoniae vaccine","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"St. Jude Children","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"St. Jude Children \/ Blue Water Vaccines","highestDevelopmentStatusID":"1","companyTruncated":"St. Jude C.."},{"orgOrder":0,"company":"Arrevus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Presents Preclinical Results for GJB2 Gene Therapy Collaboration and Cisplatin Otoprotection Program","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"GJB2 Gene Therapy","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Arrevus","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arrevus \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Arrevus \/ .."},{"orgOrder":0,"company":"Akouos","sponsor":"Pivotal bioVenture Partners","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"Akouos Closes $105 Million Series B Financing","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"AK-OTOF","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0.11,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Akouos \/ Pivotal bioVenture Partners","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ P.."},{"orgOrder":0,"company":"Akouos","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hearing loss biotech Akouos files for a $100 million IPO","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"AK-OTOF","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0.10000000000000001,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Akouos \/ BofA Securities","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ B.."},{"orgOrder":0,"company":"Novus Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"DPPC","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Novus Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Novus Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novus Ther.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Announces Positive Preliminary Preclinical Data From Its Otoferlin Gene Therapy Program","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"OTOF-GT","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Provides Update on Clinical Trials and Development Programs","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sound Pharma Advances Pivotal Phase 3 Clinical Trials in Meniere's Disease","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ebselen","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Sound Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sound Phar.."},{"orgOrder":0,"company":"ALK","sponsor":"Otonomy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ALK Enters into Co-Promotion Agreement with Otonomy for OTIPRIO\u00ae, the First and Only Single-Dose Treatment for Acute Otitis Externa","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"ALK","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"ALK \/ Otonomy","highestDevelopmentStatusID":"12","companyTruncated":"ALK \/ Oton.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis receives positive CHMP opinion for new Xolair\u00ae indication to treat severe chronic rhinosinusitis with nasal polyps","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Omalizumab","moa":"IgE","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Reports Positive Top-Line Results from Phase 1\/2 Clinical Trial of OTO-313 in Patients with Tinnitus","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Gacyclidine","moa":"NMDA receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Provides Update on OTIVIDEX\u00ae Program","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"KALEO INC","sponsor":"Optinose","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Optinose Announces XHANCE Co-Promotion Agreement with Kal\u00e9o","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"KALEO INC","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"KALEO INC \/ Optinose","highestDevelopmentStatusID":"12","companyTruncated":"KALEO INC .."},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pipeline Therapeutics Initiates Phase 1\/2a Clinical Trial of PIPE-505 in Sensorineural Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"PIPE-505","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Contineum Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Contineum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Contineum .."},{"orgOrder":0,"company":"KYORIN PHARMACEUTICAL CO LTD","sponsor":"Otonomy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Otonomy Announces Exclusive License Agreement with Kyorin for Novel Compound in OTO-6XX Hearing Loss Program","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"OTO-6XX","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"KYORIN PHARMACEUTICAL CO LTD","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KYORIN PHARMACEUTICAL CO LTD \/ Otonomy","highestDevelopmentStatusID":"4","companyTruncated":"KYORIN PHA.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Auris Medical Announces Completion of Enrollment into First Part of TRAVERS Phase 2 Study with AM-125 in Vertigo","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis receives EC approval for new Xolair\u00ae indication to treat severe chronic rhinosinusitis with nasal polyps","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Omalizumab","moa":"IgE","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genentech","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnaptysBio's Etokimab Provides More Disappointing Results, Raising Questions About Compound's Future","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Etokimab","moa":"Interleukin-33","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK\u2122","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Fennec Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fennec Pha.."},{"orgOrder":0,"company":"Autifony Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$50.1 million","upfrontCash":"$29.5 million","newsHeadline":"Autifony Therapeutics Regains Rights to Clinical Stage Kv3 Programme","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Termination","leadProduct":"AUT00206","moa":"Kv3 potassium channel","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Autifony Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Autifony Therapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"6","companyTruncated":"Autifony T.."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyra Therapeutics to Present Data Supporting LYR-210 for the Treatment of Chronic Rhinosinusitis","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Lyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Auris Medical Announces Positive Interim Data from TRAVERS Phase 2 Study with AM-125 in Vertigo","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Fasenra Met Both Co-Primary Endpoints of Reduced Nasal Polyp Size and Blockage in the Ostro Phase III Trial","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Benralizumab","moa":"IL-5 alpha receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Presents Results Demonstrating Sustained Improvement in Hearing Loss Patients Treated with FX-322","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Completes Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Auris Medical Announces Initiation of Part B of TRAVERS Phase 2 Study with AM-125 in Vertigo","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Announces Expanded FX-322 Clinical Development Program and Upcoming Day-90 Phase 2a Analysis","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$82.0 million","upfrontCash":"Undisclosed","newsHeadline":"Decibel Therapeutics Announces $82M Series D Financing to Advance Gene Therapies to Restore Hearing and Balance","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Series D Financing","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Decibel Therapeutics \/ OrbiMed","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"University of Florida","sponsor":"Decibel Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Decibel Therapeutics Announces Exclusive Licensing Agreements for Hearing Loss Gene Therapy Technology","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"University of Florida","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Florida \/ Decibel Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glenmark to Sell Select Anti-Allergy Brands to Dr Reddy\u2019s in Russia, Ukraine, Kazakhstan and Uzbekistan for its \u201cRyaltris\u201d Launch","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Divestment","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"Glenmark Pharmaceuticals \/ Dr Reddy\u2019s Lab","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Provides Update on OTIVIDEX\u00ae and OTO-313 Programs","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Xolair\u00ae (Omalizumab) for Adults with Nasal Polyps","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Remiges Ventures","pharmaFlowCategory":"D","amount":"$12.8 million","upfrontCash":"Undisclosed","newsHeadline":"Cyrano Therapeutics Raises $12.8 Million to Complete Phase 2 Trial of CYR-064 for the Restoration of Chronic Smell and Flavor Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Series A Financing","leadProduct":"CYR-064","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0.01,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.01,"dosageForm":"Intranasal spray","sponsorNew":"Cyrano Therapeutics \/ Remiges Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano The.."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Reports Positive Top-Line Results from Phase 1\/2 Clinical Trial of OTO-413 in Patients with Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Brain-Derived Neurotrophic Factor","moa":"BDNF","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"Creighton University School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study identifies Repurposed Drug with Potential to Protect Hearing","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Dabrafenib Mesylate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Creighton University School of Medicine","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Creighton University School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Creighton .."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Barclays","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hearing Disorder Biotech Decibel Therapeutics Files for a $75 Million IPO","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Public Offering","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Decibel Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Barclays","highestDevelopmentStatusID":"4","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Decibel Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Decibel and Catalent Sign Development and Manufacturing Agreement for Dual-Vector Gene Therapy for the Treatment of Congenital Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Catalent Pharma Solutions \/ Decibel","highestDevelopmentStatusID":"4","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"DBTX","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hearing Disorder Biotech Decibel Therapeutics Sets Terms for $100 Million IPO","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Decibel Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ DBTX","highestDevelopmentStatusID":"4","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Franklin Templeton","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pipeline Therapeutics Completes $80 Million Series C Financing","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series C Financing","leadProduct":"PIPE-505","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Contineum Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Intratympanic Injection","sponsorNew":"Contineum Therapeutics \/ Franklin Templeton","highestDevelopmentStatusID":"7","companyTruncated":"Contineum .."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Presents New Preclinical Data on SENS-401 at ARO 2021","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Decibel Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX\u00ae in Patients with M\u00e9ni\u00e8re's Disease","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Decibel Presents Promising Preclinical Findings on DB-OTO Designed to Provide Hearing to Individuals with Otoferlin Mutations","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Decibel Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Published Data from Phase 1\/2 Clinical Trial in Acquired Sensorineural Hearing Loss Patients Receiving FX-322","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"Vivimed Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivimed Labs Gets Approval from Uzbekistan Govt for Two Products","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Bilastine","moa":"H1 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Vivimed Labs","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vivimed Labs \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vivimed La.."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Releases New Data from Two FX-322 Clinical Studies; Plans to Advance Single-Dose Regimen","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Gacyclidine","moa":"NMDA","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyra Therapeutics to Present LANTERN Phase 2 Study Results for LYR\u2011210 in Oral Presentation at COSM 2021 Virtual","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Lyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Akouos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akouos Receives Orphan Drug and Rare Pediatric Disease Designations for AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"AK-OTOF","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intracochlear","sponsorNew":"Akouos \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ N.."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyra Therapeutics Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Lyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Rinri Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$14.1 million","upfrontCash":"Undisclosed","newsHeadline":"Rinri Therapeutics Raises \u00a310M from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Therapy to Restore Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Financing","leadProduct":"Stem cell therapy","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Rinri Therapeutics","amount2":0.01,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Rinri Therapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"4","companyTruncated":"Rinri Ther.."},{"orgOrder":0,"company":"Rinri Therapeutics","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"$4.5 million","upfrontCash":"Undisclosed","newsHeadline":"Rinri Therapeutics Secures Innovate UK Funding Grant for \u00a33.2m Project to Advance its Novel Cell-Based Therapy to Restore Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Funding","leadProduct":"Stem cell therapy","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Rinri Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rinri Therapeutics \/ Innovate UK","highestDevelopmentStatusID":"4","companyTruncated":"Rinri Ther.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Auris Medical Reaches Midpoint for Enrollment in Part B of AM-125 Phase 2 TRAVERS Trial in Acute Peripheral Vertigo","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Eyes Clinical Trial of Hearing Loss Gene Therapy","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fennec Pharma Resubmits NDA For Pedmark","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Fennec Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fennec Pha.."},{"orgOrder":0,"company":"Otonomy","sponsor":"ALK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ALK Acquires OTIPRIO\u00ae (Ciprofloxacin Otic Suspension), Broadening Treatment Solutions for Healthcare Providers and Patients","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Otic Suspension","sponsorNew":"Otonomy \/ ALK","highestDevelopmentStatusID":"12","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"LianBio","pharmaFlowCategory":"D","amount":"$147.0 million","upfrontCash":"$12.0 million","newsHeadline":"Lyra Therapeutics and LianBio Announce Strategic Partnership and Exclusive License Agreement for LYR-210","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Partnership","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0.14999999999999999,"dosageForm":"Sustained Topical Implant","sponsorNew":"Lyra Therapeutics \/ LianBio","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Initiates Expansion of Phase 1\/2 Clinical Trial for OTO-413 in Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Brain-Derived Neurotrophic Factor","moa":"BDNF","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"Akouos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Committee Recommends Orphan Drug Designation for Akouos\u2019 AK-OTOF","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"AK-OTOF","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intracochlear","sponsorNew":"Akouos \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ N.."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Decibel Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Decibel Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyra Therapeutics to Highlight LYR-210 and LYR-220 Clinical Programs at Virtual Event with Leading Clinical CRS Experts","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Sustained Topical Implant","sponsorNew":"Lyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"Sensorion","sponsor":"Cochlear Limited","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Surpasses Enrollment Target for SENS-401 in SSNHL, Results Available in January 2022","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Cochlear Limited","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Optinose","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Optinose Completes Patient Recruitment in Second Pivotal Trial for XHANCE in Chronic Sinusitis","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Optinose","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Optinose \/.."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NUCALA (Mepolizumab) The First and Only Anti-Il-5 Add-On Treatment Approved in Canada that Targets Eosinophilic Inflammation in Adults with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Mepolizumab","moa":"IL-5","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"Optinose","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$46.0 million","upfrontCash":"Undisclosed","newsHeadline":"Optinose Announces Closing of $46.0 Million Public Offering of Common Stock","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Public Offering","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Optinose","amount2":0.050000000000000003,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0.050000000000000003,"dosageForm":"Intranasal","sponsorNew":"Optinose \/ Piper Sandler","highestDevelopmentStatusID":"12","companyTruncated":"Optinose \/.."},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fennec Pharmaceuticals Expects To Receive Complete Response Letter From The Fda For Its New Drug Application For Pedmark\u2122 To Prevent Ototoxicity Associated With Cisplatin In Pediatric Patients With Localized, Non-Metastatic, Solid Tumors","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Fennec Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fennec Pha.."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Decibel Therapeutics Reports on Continued Progress of Lead Gene Therapy Product Candidate DB-OTO and Presents Promising Preclinical Data Supporting Importance of Cell-Selective Transgene Expression Across Gene Therapy Pipeline","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Decibel Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Association for Research in Otolaryngology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion to Present Three Posters on SENS-401 in Cisplatin Ototoxicity Modelsat the Association for Research in Otolaryngology (ARO) 45th Annual MidWinter Meeting","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Association for Research in Otolaryngology","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Enrolls First Patient in Phase 2\/3 Sinusitis Trial of Nurtec\u00ae ODT","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Gacyclidine","moa":"NMDA","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"Optinose","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Optinose","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Optinose \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on US Regulatory Review of Fasenra in Chronic Rhinosinusitis with Nasal Polyps","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Benralizumab","moa":"IL-5 alpha receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Organon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Perrigo Announces U.S. Fda Approval For Otc Use Of Nasonex\u00ae 24hr Allergy","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Perrigo Company plc","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Perrigo Company plc \/ Organon LLC","highestDevelopmentStatusID":"12","companyTruncated":"Perrigo Co.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Will Present at the
Market Place